Life Sciences

  • April 23, 2026

    ITC Investigating Chinese Biopharma Chemicals Over Pricing

    The U.S. International Trade Commission is looking into whether Chinese imports of two chemicals used in biopharma manufacturing that are allegedly being sold at unfair prices are harming U.S. domestic industry, it said in a notice published Thursday.

  • April 23, 2026

    DOJ Says Medical Pot Shift Shouldn't Affect Gun Rights Case

    Despite an order from the U.S. Department of Justice loosening federal restrictions on medical marijuana, the Trump administration signaled Thursday that it does not intend for the changes to cannabis regulation to apply retroactively.

  • April 23, 2026

    Trulieve Says Infringement Suit Doesn't Actually State A Claim

    Cannabis company Trulieve Inc. has said a rival company's complaint against it lacks any factual basis to support the allegation Trulieve infringed the rival's patents, urging a Florida federal court to throw out the suit.

  • April 23, 2026

    DOJ Final Order Loosens Rules For State-Legal Medical Pot

    The U.S. Department of Justice published a final order Thursday loosening federal restrictions on medical marijuana products that fall within the ambit of state-regulated programs or have approval from the U.S. Food and Drug Administration.

  • April 22, 2026

    Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid

    The full Federal Circuit on Wednesday rejected Sarepta Therapeutics Inc.'s bid for a rehearing after a panel's decision revived a University of Pennsylvania gene therapy patent that is licensed by clinical-stage biotechnology company Regenxbio Inc.

  • April 22, 2026

    Bayer 'Natural' Vitamin Buyer Classes Affirmed By 9th Circ.

    A split Ninth Circuit on Tuesday upheld a federal district court's certification of New York and California classes of consumers who bought Bayer Healthcare multivitamin gummies that were allegedly labeled falsely as "natural," finding the company "demands more" from the plaintiffs at this stage of the litigation than certification requires. 

  • April 22, 2026

    Eli Lilly Case Over Weight Loss Drugs Kept Mostly Intact

    A California federal court has refused to throw out a lawsuit from Eli Lilly against a telehealth company and related entities over the compounding of its popular weight loss drugs Mounjaro and Zepbound, but agreed to trim a conspiracy claim from the case.

  • April 22, 2026

    Justices Would Back Vax Law Challenge, 2nd Circ. Told

    The U.S. Supreme Court's March 2 decision in a California gender-related school policy case requires the Second Circuit to advance a 2023 challenge to Connecticut's preschool and daycare student vaccine mandates, an attorney for a Constitution State congregation told a three-judge panel on Wednesday.

  • April 22, 2026

    Judge Lets Pharma Co. Seal Parts Of Ex-GC's Retaliation Suit

    A Texas state judge on Wednesday granted Houston-based Empower Clinic Services LLC's bid to permanently and partially seal a petition by its former general counsel that alleges a smear campaign by the company after he confronted them about conduct he said was unlawful.

  • April 22, 2026

    Sorrento, M3 Get Pause On RICO Suit Naming Jackson Walker

    A Texas bankruptcy judge on Wednesday agreed to put on hold a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection there.

  • April 22, 2026

    Oura Hit With New Patent Suit Over Fitness Wearables

    Zepp Health has hit Oura Health with a lawsuit in the Eastern District of Texas accusing the Finnish company of infringing a series of patents on wearable fitness devices, the latest salvo in a wider patent fight between the companies.

  • April 22, 2026

    Ex-Conn. Prosecutor Fights Drug Co. Bid To Appeal DQ Denial

    Insurers Humana Inc. and Molina Healthcare Inc. urged a federal judge to turn down a group of generic-drug makers' request for an immediate trip to the Third Circuit, arguing the drugmakers' bid for a second chance to disqualify Connecticut's former assistant attorney general from an antitrust case was not qualified for an interlocutory appeal.

  • April 22, 2026

    4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy

    Biopharmaceutical company Amneal Pharmaceuticals Inc. on Wednesday unveiled plans to acquire biosimilars-focused Kashiv BioSciences LLC in a deal worth up to $1.1 billion that was built by four law firms.

  • April 22, 2026

    Chancery Sends Masimo Ex-CEO Pay Fight To California

    The Delaware Chancery Court sided with former Masimo Corp. CEO Joe E. Kiani in his fight with the global medical technology company, dismissing the company's lawsuit over a disputed $450 million severance package and ruling that the case must proceed in California, not Delaware.

  • April 21, 2026

    Armistice Capital Head Calls COVID Stock Rise 'Fun,' 'Lucky'

    Armistice Capital's founder defended his hedge fund Tuesday from claims it pump-and-dumped $250 million in Vaxart stock during the COVID-19 pandemic, telling a California federal jury that he and his fund got "lucky" and that the stock's rapid surge was "fun."

  • April 21, 2026

    Merck Beats Minn. Hockey Player's Talc Mesothelioma Claims

    A Chicago jury has found Merck & Co. not liable for a hockey player's mesothelioma allegedly caused by the Dr. Scholl's talc foot powder he used regularly for years.

  • April 21, 2026

    Biotech Co. Investors Clash Over 'Self-Dealing' Claim

    Attorneys for a biopharmaceutical and technology company stockholder and a group of venture investors sharply disagreed Tuesday over whether a financing deal was a lifeline for a struggling company or a self-serving maneuver that enriched insiders, as they argued a motion to dismiss the derivative suit in the Delaware Chancery Court.

  • April 21, 2026

    Congress Rallies More For Bills On Copyrights Than Patents

    There have been more intellectual property bills floated in Congress that are supportive of copyright rights than patent rights, according to a new report looking at how lawmakers treat the IP system.

  • April 21, 2026

    Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge

    A former Amgen Inc. employee filed a proposed class action in California federal court Tuesday alleging the biotech company discriminatorily imposes an "egregiously high" $150-a-month surcharge on employees who use tobacco products, while failing to adequately notify them of reasonable pathways to avoid the fees, in violation of federal benefits law.

  • April 21, 2026

    Pfizer, Dexcel Take 2 Patents Off Table For Bench Trial

    Drugmaker Pfizer and an Israeli competitor that is seeking to create a generic version of a Pfizer heart medication said Tuesday they have reached an agreement to remove two asserted patents from a trial set to start next week.

  • April 21, 2026

    Fed. Circ. Keeps Banner Witcoff And Saiber Off Patent Case

    The Federal Circuit kept intact the disqualification of two law firms from a patent ownership fight on Tuesday, saying it had not been shown a district judge made a clear error in removing them.

  • April 21, 2026

    Pot Management Co. Says It's Allowed Biz Tax Deduction

    A California-based management company linked to cannabis operations is challenging the IRS over a $4.2 million tax bill, according to a U.S. Tax Court petition, arguing that the company does not traffic in controlled substances that would otherwise bar it from claiming business deductions.

  • April 21, 2026

    Squires Stands By Ending Skincare IPR Over ITC Overlap

    U.S. Patent and Trademark Office Director John Squires has shot down Sinclair Pharma Ltd.'s request to revive its challenge to Hydrafacial LLC's skin treatment patent, which the director had terminated based on related proceedings at the U.S. International Trade Commission.

  • April 21, 2026

    Novo Nordisk Unit Can't Slip Former Exec's Sex, Age Bias Suit

    A Novo Nordisk unit must face a former finance director's lawsuit claiming she was fired because she was an older woman who complained about a male co-worker's behavior, with a North Carolina federal judge ruling her allegations were detailed enough to stay in court.

  • April 21, 2026

    Purdue Pharma Sentencing Punted For In-Person Attendance

    A New Jersey federal judge delayed Oxycontin maker Purdue Pharma's criminal sentencing by a week, saying rescheduling would give an in-person attendance option to hundreds of observers who tuned in virtually Tuesday.

Expert Analysis

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.